Multi-target therapies may address combined hypertension and dyslipidemia pathophysiology
Multi-Target Therapies May Address Combined Hypertension and High Cholesterol
This systematic review synthesizes evidence on synergistic mechanisms of hypertension and dyslipidemia, highlighting the RAAS/PPAR axis, AMP…
Combining treatments like statins and RAAS inhibitors may offer a more precise way to manage both high blood pressure and cholesterol levels…
SGLT2 inhibitors provide robust prognostic benefits in heart failure with inconsistent results in post-myocardial infarction settings
SGLT2 inhibitors show promise for heart failure and diabetes
This narrative review examines the cardiovascular and metabolic effects of SGLT2 inhibitors, specifically empagliflozin and dapagliflozin. T…
New evidence shows how SGLT2 inhibitors may protect the heart and manage risks for patients with type 2 diabetes and heart failure.
Systematic review suggests modest risk reduction with SGLT2 inhibitors or ARNIs added to standard therapy in severe heart failure
Moderate evidence supports adding SGLT2 inhibitors to heart failure treatment
This systematic review and network meta-analysis evaluated adding SGLT2 inhibitors or angiotensin receptor-neprilysin inhibitors to neurohor…
A large analysis suggests adding SGLT2 inhibitors may lower risk of death or hospitalization for heart failure, though caution is advised.
Network meta-analysis ranks FGF21 analogs and SGLT2 inhibitors highest for MASH fibrosis
New analysis shows SGLT2 inhibitors may help liver scarring improve in adults with fatty liver disease
A network meta-analysis of 34 trials found FGF21 analogs and SGLT2 inhibitors ranked highest for improving liver fibrosis in MASH, with GLP-…
A large review of trials found SGLT2 inhibitors ranked highest for reducing liver scarring. These drugs also showed good safety and balanced…
Real-time CGM improved HbA1c versus SMBG in adults with type 2 diabetes on basal insulin and modern therapies
Real-time glucose monitoring improves blood sugar control in type 2 diabetes
This randomised controlled trial compared real-time continuous glucose monitoring against standard self-monitoring of blood glucose in adult…
A new trial shows continuous glucose monitoring helps lower blood sugar levels better than standard finger-prick testing for adults with typ…
SGLT2 and dual SGLT1/2 inhibitors reduce cardiovascular death or heart failure hospitalization risk in type 2 diabetes patients
Three diabetes drugs lower heart failure and heart attack risk
This network meta-analysis evaluates bexagliflozin, ertugliflozin, and sotagliflozin versus placebo for patients with type 2 diabetes. The a…
Three newer diabetes drugs cut heart failure and heart attack risk in people with type 2 diabetes, a new analysis finds.
SGLT2 inhibitor use associated with increased diabetic ketoacidosis risk, especially with elevated HbA1c
New review shows SGLT2 drugs raise DKA risk when blood sugar is high
This meta-analysis of observational and randomized trials found SGLT2 inhibitor use is associated with an increased risk of diabetic ketoaci…
A big review of many studies found that medicines for diabetes called SGLT2 inhibitors can increase the chance of a serious condition called…
Triple oral therapy with metformin, SGLT-2, and DPP-4 inhibitors lowers HbA1c better than dual regimens in adults with type 2 diabetes
Triple oral diabetes drugs lower blood sugar better than two-drug regimens
A systematic review and meta-analysis of 2,606 adults with type 2 diabetes found that triple oral therapy combining metformin, an SGLT-2 inh…
A large analysis shows that taking three specific oral diabetes medicines together lowers blood sugar more effectively than taking just two …
Narrative review examines metabolic syndrome and novel agents in kidney transplant recipients
Kidney transplant patients face high metabolic risks and rejection
This narrative review addresses antibody-mediated rejection and metabolic syndrome in kidney transplantation recipients. The authors note th…
About half of kidney transplant recipients develop metabolic problems within a year, while antibody-mediated rejection remains a major cause…
Network meta-analysis of finerenone and SGLT2 inhibitors in heart failure with preserved or mildly reduced ejection fraction
New analysis shows finerenone and SGLT2 drugs help lower heart failure hospitalization risks for patients with preserved ejection fraction
This network meta-analysis evaluated finerenone, sodium–glucose cotransporter 2 inhibitors, renin–angiotensin system inhibitors, and angiote…
A large review of over 65,000 patients found that finerenone and SGLT2 inhibitors reduce hospital stays and worsening heart failure compared…
Combining finerenone with SGLT2 inhibitors lowers mortality and cardiovascular events in diabetic chronic kidney disease patients
A Two-Drug Combo May Save Lives in Diabetic Kidney Disease
A meta-analysis of 1,580 patients shows dual therapy with finerenone and SGLT2 inhibitors significantly reduces mortality and kidney events …
A new analysis finds that pairing finerenone with an SGLT2 inhibitor may significantly lower the risk of death and heart problems for people…
Network meta-analysis compares bexagliflozin efficacy and safety with other SGLT2 inhibitors in type 2 diabetes
New analysis shows bexagliflozin helps lower blood sugar and weight in adults with type 2 diabetes compared to other drugs
This systematic review and network meta-analysis synthesized evidence on bexagliflozin versus other SGLT2 inhibitors and placebo in adults w…
A large review of 26,838 patients found bexagliflozin lowers blood sugar and weight well. It also lowers blood pressure and causes fewer inf…